Experience

Davis Polk advised the joint book-running managers in connection with the $226.3 million public offering of common stock of Xencor, Inc. The common stock is listed on the NASDAQ Global…

Davis Polk advised the joint book-running managers in connection with a $69 million SEC-registered common stock offering by Corvus Pharmaceuticals, Inc. The common stock is listed on the…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with two SEC-registered follow-on offerings of common stock of Atara…

Davis Polk advised the representatives of the several underwriters in an SEC-registered offering of $2.1 billion in aggregate principal amount of Anthem, Inc.’s senior notes, consisting of …

Davis Polk advised the joint book-running managers in connection with a $176 million SEC-registered offering of 5,500,000 shares of common stock of Aimmune Therapeutics, Inc. Aimmune…

Davis Polk advised ViewRay, Inc. in a direct-registered offering of 7,090,581 shares of ViewRay’s common stock and 1,418,116 warrants to purchase shares of ViewRay’s common stock for…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on an SEC-registered offering by Celgene Corporation of $500 million aggregate…

Davis Polk advised the initial purchasers on a Rule 144A offering by Avadel Finance Cayman Limited, a wholly owned subsidiary of Avadel Pharmaceuticals plc, of $143.7 million aggregate…

Davis Polk advised Affimed N.V. on its $26.5 million public offering of 13,225,000 of its common shares. Included in the shares are 1,725,000 shares sold by Affimed pursuant to the…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $800 million acquisition of MPI Research Inc. The transaction, which is expected to close early in…